INDUSTRY
An important aspect of the CoE is its interactions with industrial partners, to whom it offers extensive research and development expertise and facilities, as well as accelerated discovery and commercialization path that facilitates introduction of new products and services that enhance the field of medicine. The promise of personalized medicine ultimately depends upon the close working relationship between researchers working in labs and those who ultimately bring new discoveries to patients, health care providers and other constituents across the world.
The CoE’s industry collaborations are targeted to these primary life sciences industry sectors
The CoE has already initiated a number of high profile, high-potential interactions with the life sciences industry involving both domestic and global partners in collaborations that blends the strengths of the CoE’s translational research programs, facilities and commercialization resources with the industry goals of private sector partners. To learn more about industry collaborations with the CoE, click here.
INDUSTRY HIGHLIGHTS
Buffalo-Made Anti-Cancer Drug Begins Human Trials
11/16/2007 - BUFFALO, N.Y. -- An anti-cancer drug developed by Kinex Pharmaceuticals of Buffalo and a University at Buffalo faculty researcher has begun clinical testing with patients. As part of FDA-mandated phase 1 testing, KX2-391 is being administered to a group of patients with advanced cancer who have not responded to other therapies. In non-human testing, the drug has been shown to be active against all cancers, according to Kinex Pharmaceuticals CEO Allen Barnett.
KX2-391 may be the first small-molecule drug discovered and developed in Buffalo that has progressed to the human trial stage. The phase 1 trial is a first step toward FDA approval of the drug and is intended to test the safety and dosage tolerability of the drug. "We're very excited about the drug's potential," Barnett says. "As we go further in the drug's development, and do broader testing, we get better and better data. If the drug works half or a third as well as it's worked in pre-clinical trials, it will have blockbuster, billion-dollar potential." ...[Read On...]
Featured Researcher
David Hangauer, Ph.D.
Associate Professor, Department of Chemistry
Dr. Hangauer is a leader in the field of structure based drug design. Following graduate studies at the University at Buffalo, he spent ten years at Merck Sharp and Dohme Research Laboratories where he directed a variety of drug discovery projects. In 1989, Dr. Hangauer returned to academia and joined the chemistry faculty at SUNY Buffalo where he has had a productive career that has focused on developing protein kinase inhibitors.
Dr. Hangauer's expertise is highly sought by pharmaceutical and biotechnology companies worldwide, underscoring his level of expertise and his recognition as a major contributor to commercial drug discovery efforts.
[ Dr. David Hangauer's Website]
News
Study Describes Mechanism Linking Alcohol with Risk of Breast Cancer
04/30/2008 - BUFFALO, N.Y. -- The known association of alcohol consumption with an increased risk of breast cancer has been linked by researchers at the University at Buffalo to a process that causes genes that promote normal cell growth to produce proteins that precipitate unregulated cell growth, an action known as hypermethylation...[Read On...]
Common Plant Component Shows Potential as MS Treatment
04/17/2008 - BUFFALO, N.Y. -- Plant sterols, known to help reduce high cholesterol, also may be effective in treating the effects of multiple sclerosis (MS), novel research by University at Buffalo investigators has shown. The study, lead by Forum M. Desai, a student in the UB Department of Exercise and Nutrition Sciences, has shown that Beta-sitosterol, a compound found in most vegetables and fruits, can reduce secretion of several proinflammatory factors known to be involved in damage to the brain's myelin...[Read On...]
Visit the News Archive
Events
May 6 - Dr. Austin Clean Room Program
Don’t miss the opportunity to hear one of the world’s foremost Cleanroom and Contamination Control Experts. Dr. Austin has published six textbooks on clean rooms and personally authored each of the clean room standards adopted by ISO. This program will take place from 2-6pm Roswell Park Cancer Institute, Center for Genetics & Pharmacology, Zebro Room, 701 Ellicott Street, Buffalo, NY. Register at www.thepartnership.org/events. See flyer for more information. 
May 8 – HWI Seminar Series
Please join Dr. Michael Rossman from Purdue University for a presentation on “Symmetry and asymmetry in the control of viral assembly, maturation and infection”. Program begins at 2:30pm with a reception to follow. Series is held at the Hauptman-Woodward Institute 700 Ellicott Street, Buffalo, NY 14203.
To view the complete list of events and event details, please visit our Events page
To receive periodic News & Events emails from the COE, please join our mailing list!
